Immunization with hybrid proteins containing the membrane proximal external region of HIV-1

AIDS Research and Human Retroviruses

Volumn 30, Issue 5, 2014, Pages 498-508

  Strasz, Nicola ^a   Morozov, Vladimir A ^a   Kreutzberger, Jürgen ^a   Keller, Martina ^a   Eschricht, Magdalena ^a   Denner, Joachim ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CARDIOLIPIN; GLYCOPROTEIN GP 41; HYBRID PROTEIN; MEMBRANE PROTEIN; MEMBRANE PROXIMAL EXTERNAL REGION; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; SPHINGOMYELIN; UNCLASSIFIED DRUG; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY ISOLATION; ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DRUG ANTIGENICITY; DRUG CONFORMATION; EPITOPE MAPPING; GOAT; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN NL4.3); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; VACCINATION; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; SERODIAGNOSIS; WISTAR RAT;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; GOATS; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; NEUTRALIZATION TESTS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 84899790874     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0191     Document Type: Article

References (47)

1. Doria-Rose NA, Klein RM, Manion MM, et al.: Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly crossneutralizing antibodies. J Virol 2009;83(1):188-199
2. Sather DN, Armann J, Ching LK, et al.: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009;83(2):757-769
3. Walker LM and Burton DR: Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr Opin Immunol 2010;22(3):358-366
4. Dimitrov AS, Louis JM, Bewley CA, Clore GM, and Blumenthal R: Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 2005;44(37):12471- 12479
5. Chan DC and Kim PS: HIV entry and its inhibition. Cell 1998;93(5):681-684
6. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, and Weissenhorn W: Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 2010;6(5):e1000880
7. He Y, Liu S, Li J, et al.: Conserved salt bridge between the N-and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol 2008;82(22): 11129-11139
8. Shen X, Parks RJ, Montefiori DC, et al.: In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009;83(8):3617-3625
9. Huang J, Ofek G, Laub L, et al.: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012;491(7424):406-412
10. Bomsel M, Tudor D, Drillet AS, et al.: Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011;34(2):269-280
11. Wang J, Tong P, Lu L, et al.: HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One 2011;6(3):e18233
12. Arnold GF, Velasco PK, Holmes AK, et al.: Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009;83(10):5087-5100
13. Ye L, Wen Z, Dong K, et al.: Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One 2011;6(5):e14813
14. Mascola JR and Montefiori DC: The role of antibodies in HIV vaccines. Annu Rev Immunol 2010;28:413-444
15. Kwong PD, Mascola JR, and Nabel GJ: Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011;1(1):a007278
16. Guenaga J, Dosenovic P, Ofek G, et al.: Heterologous epitope-scaffold prime: Boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011;6(1):e16074
17. Matyas GR, Wieczorek L, Beck Z, et al.: Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009;23(16):2069-2077
18. Watson DS and Szoka FC Jr: Role of lipid structure in the humoral immune response in mice to covalent lipidpeptides from the membrane proximal region of HIV-1 gp41. Vaccine 2009;27(34):4672-4683
19. Fiebig U, Stephan O, Kurth R, and Denner J: Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: Basis for a vaccine for xenotransplantation? Virology 2003;307(2):406-413
20. Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, and Denner J: Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). Virology 2011; 411(1):78-86
21. Fiebig U, Hartmann MG, Bannert N, Kurth R, and Denner J: Transspecies transmission of the endogenous koala retrovirus. J Virol 2006;80(11):5651-5654
22. Langhammer S, Fiebig U, Kurth R, and Denner J: Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 2005;23(25):3341-3348
23. Langhammer S, Fiebig U, Kurth R, and Denner J: Increased neutralizing antibody response after simultaneous immunization with leucogen and the feline leukemia virus transmembrane protein. Intervirology 2010;54(2):78-86
24. Langhammer S, Hubner J, Kurth R, and Denner J: Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E. Immunology 2006;117(2):229-237
25. Langhammer S, Hubner J, Jarrett O, Kurth R, and Denner J: Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: Absence of antigenemia following challenge. Antiviral Res 2011;89(1):119-123
26. Fiebig U, Schmolke M, Eschricht M, Kurth R, and Denner J: Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope. AIDS 2009;23(8): 887-895
27. Hager-Braun C, Katinger H, and Tomer KB: The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J Immunol 2006;176(12):7471-7481
28. Bellamy-McIntyre AK, Lay CS, Baar S, et al.: Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 2007;282(32):23104-23116
29. Noah E, Biron Z, Naider F, Arshava B, and Anglister J: The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the sixhelix bundle formed with a matching N' peptide. Biochemistry 2008;47(26):6782-6792
30. Bussow K, Cahill D, Nietfeld W, et al.: A method for global protein expression and antibody screening on highdensity filters of an arrayed cDNA library. Nucleic Acids Res 1998;26(21):5007-5008
31. Montefiori DC: Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009;485: 395-405
32. Behrendt R, Fiebig U, Norley S, Gurtler L, Kurth R, and Denner J: A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR. J Virol Methods 2009;159(1):40-46
33. Behrendt R, Fiebig U, Schmolke M, Kurth R, and Denner J: Induction of antibodies specific for Gp41 of HIV-1 by gene gun DNA vaccination. J Vaccines Vaccin 2012;3(145):2
34. Geonnotti AR, Bilska M, Yuan X, et al.: Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxinmediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses 2010;26(3):279-291
35. Dennison SM, Anasti K, Scearce RM, et al.: Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol 2011;85(3): 1340-1347
36. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999;5(2):204-210
37. Mascola JR, Lewis MG, Stiegler G, et al.: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73(5):4009-4018
38. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6(2):207-210
39. Ferrantelli F, Rasmussen RA, Buckley KA, et al.: Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004;189(12):2167-2173
40. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6(2):200-206
41. Hessell AJ, Poignard P, Hunter M, et al.: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009;15(8):951-954
42. Li J, Chen X, Jiang S, and Chen YH: Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. Biochem Biophys Res Commun 2008;376(1):60-64
43. Haynes BF: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308(5730):1906-1908
44. Scherer EM, Zwick MB, Teyton L, and Burton DR: Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007;21(16):2131-2139
45. Vcelar B, Stiegler G, Wolf HM, et al.: Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007;21(16):2161-2170
46. Matyas GR, Beck Z, Karasavvas N, and Alving CR: Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009;1788(3):660-665
47. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, and Moutsopoulos HM: Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: Comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999;13(3): 347-355.